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Abstract
Background: In spite of increasing reports of dengue and chikungunya activity in Tanzania, limited research has
been done to document the general epidemiology of dengue and chikungunya in the country. This study aimed
at determining the sero-prevalence and prevalence of acute infections of dengue and chikungunya virus among
participants presenting with malaria-like symptoms (fever, headache, rash, vomit, and joint pain) in three communities
with distinct ecologies of north-eastern Tanzania.
Methods: Cross sectional studies were conducted among 1100 participants (aged 2–70 years) presenting with
malaria-like symptoms at health facilities at Bondo dispensary (Bondo, Tanga), Hai hospital (Hai, Kilimanjaro)
and TPC hospital (Lower Moshi). Participants who were malaria negative using rapid diagnostic tests (mRDT)
were screened for sero-positivity towards dengue and chikungunya Immunoglobulin G and M (IgG and IgM)
using ELISA-based kits. Participants with specific symptoms defined as probable dengue and/or chikungunya
by WHO (fever and various combinations of symptoms such as headache, rash, nausea/vomit, and joint pain)
were further screened for acute dengue and chikungunya infections by PCR.
Results: Out of a total of 1100 participants recruited, 91.2 % (n = 1003) were malaria negative by mRDT.
Out of these, few of the participants (<5 %) were dengue IgM or IgG positive. A total of 381 participants had fever
out of which 8.7 % (33/381) met the defined criteria for probable dengue, though none (0 %) was confirmed to be
acute cases. Chikungunya IgM positives among febrile participants were 12.9 % (49/381) while IgG positives were
at 3.7 % (14/381). A total of 74.2 % (283/381) participants met the defined criteria for probable chikungunya and
4.2 % (11/263) were confirmed by PCR to be acute chikungunya cases. Further analyses revealed that headache
and joint pain were significantly associated with chikungunya IgM seropositivity.
Conclusion: In north-eastern Tanzania, mainly chikungunya virus appears to be actively circulating in the population.
Continuous surveillance is needed to determine the contribution of viral infections of fever cases. A possible
establishment of arboviral vector preventive control measures and better diagnosis of pathogens to avoid
over-treatment of other diseases should be considered.
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Background
Dengue and chikungunya are major global health con-
cerns due to their continued spread and intensifying
epidemic activities throughout most of the tropical and
subtropical regions of the world. Regular outbreaks of
dengue have been reported throughout most of the
tropical and sub-tropical regions of the world for several
decades [1–3] while chikungunya epidemics have attained
global distribution within the past ten years; yet large-
scale epidemics of dengue fever and chikungunya fever
has only recently presented as an emerging phenomenon
in Africa [4].
These viruses are transmitted between humans by the
bite of infected Aedes aegypti mosquitoes, furthermore
chikungunya has increased its geographical range by its
ability to infect Aedes albopictus [5, 6]. Most arbovirus
infections are asymptomatic [7], but can as well cause a
broad spectrum of manifestations, ranging from nonspe-
cific flu-like syndrome to severe complications [8, 9].
Tanzania, as many other African countries, is experi-
encing a shift in disease transmission patterns with
regards to febrile infectious diseases. While the number
of cases of malaria are decreasing in several countries
of sub-Saharan Africa [10–13], the number of febrile
cases due to other causes than malaria are still high
[14]. Various arboviruses are most likely important and
are gaining more prominence as observed through an
increase in reported activity [15–18] and epidemic activity
of diseases such as dengue and chikungunya [1, 19–21].
Moreover, malaria may as well have been over-diagnosed
in different parts of Tanzania [22–24], mainly due to lack
of differential pathogen diagnosis apart from malaria [25],
including dengue and chikungunya. Recent studies in
Tanzania have revealed that patients with acute dengue
and chikungunya infection are often misdiagnosed and
treated with anti-malarials or antibiotics [22, 26]. The
consequences of misdiagnosis and underreporting of
other diseases than malaria include economic loss [27],
development of drug resistant malaria strains (due to
over-prescribing of antimalarials) [28] and risks of increased
morbidity and mortality [29].
Little is known about the general epidemiology of
dengue and chikungunya in Africa and Tanzania in par-
ticular. Thus, the objective of this study was to determine
the sero-prevalence and as well, prevalence of acute infec-
tions of dengue and chikungunya virus among participants
presenting with malaria-like symptoms (fever, headache,
rash, vomit, and joint pain) in three communities with
distinct ecologies of North-eastern Tanzania.
Methods
Study sites
We conducted cross sectional studies at three sites in
north-eastern Tanzania; Bondo dispensary (Bondo, Tanga),
Hai hospital (Hai, Kilimanjaro) and TPC hospital (Lower
Moshi) in May 2013, November 2013 and May 2014,
respectively. These sites were selected based on variation
in precipitation pattern and varying altitude between the
sites resulting in difference in malaria transmission, and as
well, evidence of overdiagnosis of malaria [22]. Since most
malaria and arbovirus transmission occur during the rainy
seasons as a results of increased vector abundance, we
chose to conduct the surveys during the rainy seasons that
is in May and November. That is also the time when over
diagnosis of malaria is most likely to occur. Bondo is a
coastal lowland rural area in Handeni, Tanga region lo-
cated 309 m above sea level. Bondo is endemic to malaria
with a perennial transmission [30]. Hai is a sub-urban area
situated on the South-western slope of Mount Kilimanjaro
surrounded by three altitude zones ranging from highland
(1,666–1,800 m), middle (900–1666 m) and lowland zone
(900 m) above sea level. In Hai malaria transmission is
classified as moderately high in lower altitude, moderate
in mid-altitude and non-endemic in highland areas [31].
Lower Moshi is a lowland rural area located at the base of
Mount Kilimanjaro at an altitude of 800 m above sea level.
In Lower Moshi, malaria transmission occurs throughout
the year [32, 33].
Participant’s recruitment and data collection
Community sensitization to participate in the study was
done through community leaders. Inhabitants aged 2 to
70 years with specific symptoms (fever, headache, rash,
vomit, and joint pain) were encouraged to voluntarily go
for testing at the health facilities at Bondo Dispensary
Hai Hospital or TPC hospital. Individuals presenting at
the health facilities were informed of the study and on
voluntary participation. A written informed consent was
obtained from all participants and from parents or
guardians for children under 18 years of age who agreed
to participate in the study. A questionnaire was used to
collect demographic and clinical data such as age,
gender and history of illness for each of the participants.
All participants were screened for malaria by rapid diag-
nostic tests (SD BIOLINE Malaria Ag P.f/Pan) and
malaria positive patients were treated with antimalarial
according to national guidelines. In addition, auxiliary
temperature measurement was done to detect febrile
cases (>37.5 0C) and a blood sample of 0.5-1 mL was
taken from all consenting participants. A subject
number was assigned to each participant and used to
label blood samples. All samples collected in this study
were not linked to personal identifier.
IgG and IgM ELISA for detection of anti-dengue and
anti-chikungunya antibodies
Serum was separated from whole blood by centrifuga-
tion and stored at −20 °C. Anti-dengue IgM and IgG
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were detected using a direct enzyme linked immuno-
sorbent assay (ELISA) kit (SD Inc, Gyeonggi-do, Korea)
while anti-chikungunya IgM and IgG were analysed
using Indirect Elisa kits (SD, Gyeonggi-do, Korea and
IBL international, Hamburg, Germany, respectively). All
assays were performed according to the manufacturers’
procedures and all serum samples were diluted 1 into
100 with sample diluent provided with the kits. The
optical density (OD) was measured at 450 nm and the
units of antibody concentration and cut-off values cal-
culated as described by the manufacturers. Briefly, for
the Anti-dengue IgM/IgG and IgM anti-chikungunya
ELISAs the diagnostic cut-off value was calculated as
the average OD of negative controls + 0.300. For the
IgG chikungunya ELISA the threshold for positivity
was based on the OD cut-off value of the cut-of
control + 10 %.
RNA extraction, cDNA synthesis and PCR
Only serum samples from participants with specific symp-
toms (fever, headache, rash, nausea, and joint pain) who
met World Health Organization (WHO) criteria [9, 34]
for probable dengue and chikungunya definitions (see
below) were further tested by polymerase chain reaction
(PCR). Ribonucleic acid (RNA) was extracted from serum
samples using the Boom method [35]. Briefly, 30 μl of
silica was added and immediately vortexed for 5 s followed
by shaking for 10 min and centrifuged at 12,000 g for 15 s.
Supernatant was removed and silica pellets was washed
twice with 1 ml of L2 buffer (120 g of guanidine thiocyan-
ate {GuSCN} in 100 ml of 0.1 M Tris–HCl, pH 6.4), twice
with 1 ml of 70 % ethanol and once with 1 ml of acetone.
Silica pellets was dried at 56 °C for 10 min. RNA was
eluted from the silica pellets in 50 μl of diethyl pyrocarbo-
nate (DEPEC) treated water and incubated for 10 min at
56 °C. Sample was vortexed and centrifuged for 2 min at
12,000 g. 35 μl containing purified RNA was transferred
to an eppendorf tube and stored at −20 °C prior to use.
cDNA was synthesized using Superscript® VILO™ cDNA
synthesis kit (Invitrogen, life technologies, USA) according
to manufacturer’s instructions in a total volume of 20 μL
containing 2 μL of 10X Superscript® Enzyme Mix, 4 μL of
5X VILO™ reaction Mix, 11 μL of DEPEC treated water
(Ambion, USA) and 3 μL of extracted RNA. The reverse
transcription programme involved incubation at 25 °C for
10 min, extension at 42 °C for 60 min and inactivation at
85 °C for 5 min. The resulting cDNA was stored in −20 °C
for further use for dengue and chikungunya PCR.
Dengue PCR was conducted as previously described
[36] with respect to dengue only and with minor modifi-
cations using TaqMan Gene expression master mix kit
(Applied Biosystens, USA). Briefly; the reaction mixture
was composed of 5 μl of TagMan Gene Expression
master mix (Applied Biosystens, USA), 0.3 μl of each
0.25 μM forward and reverse primer, 0.14 μL of 0.125 μM
dengue probe, 3.37 μl nuclease free water (NorgenBiotek,
Canada), and 1 μl of cDNA template in a final volume of
10 μl. The amplification reaction was performed in a
Rotor-Gene Q PCR machine (Qiagen, Germany) with an
initial denaturation at 95 °C for 2 min followed by 45 cy-
cles of denaturation at 95 °C for 10 s and annealing and
extension at 60 °C for minute. All primers and probes
(Table 1) were purchased from BiolegioInc, Netherlands.
The primers (Table 1) used for conventional chikun-
gunya PCR were adopted from Reddy et al., [37] to
amplify a 646 bp gene product in the chikungunya en-
velope region of E1 (genome position: 10524–11170).
The reaction was carried out in a Bio-Rad tetrad 2,
(Biorad, USA) in a 20 μl volume containing 1 μL of
cDNA, 4 μL of 5X reaction buffer, 1.8 μL of 25 mM
MgCl2, 1.8 μL of 10 μM dNTP, 0.5 μL of 20 μM of each
primers, 0.3 μL of Go-Tag Flex DNA polymerase, and
10.3 μL of nuclease free water (NorgenBiotek, Canada).
The PCR programme consisted of an initial denaturation
at 95 °C for 2 min and 40 cycles of 30 s denaturation at
95 °C, 30 s annealing at 55 °C, 1 min elongation at 72 °C
and final extension at 72 °C for 5 min. The amplified gene
products were identified by their molecular weights ana-
lyzed by electrophoresis on a 1.5 % agarose gel stained
with ethidium bromide and visualized under UV light.
Dengue primers and probeswereadopted from Pongsir
et al., [36] for detection of dengue by real time PCR
while for chikungunya the primers wereadopted from
Reddy et al., [37] for chikungunya conventional PCR.
Case definitions
Dengue and chikungunya cases were classified according
to WHO [9, 34]. In brief, probable dengue was defined
as participants with fever and any two of the following
criteria: nausea, vomiting, rash, pains, tourniquet test
positive, leukopenia and/or a positive IgM ELISA test.
Probable chikungunya: a patient meeting both the
clinical (a characteristic triad of fever, rash and joint
manifestations plus the following: nausea, vomiting, head-
ache and/or an IgM positive test by ELISA) and epidemio-
logical criteria (residing or having visited epidemic areas).
Confirmed acute dengue or chikungunya was defined as a
positive PCR result. Prior exposure was defined as pres-
ence of anti-dengue or anti-chikungunya IgG or IgM in
serum.
Statistical analyses
Data were compiled and analyzed using SPSS 20.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Chi-square (χ2) was
used to compare categorical data while Fisher’s exact
test was used in cases when expected counts were
less than 5. Association of chikungunya seropositivity
and symptoms was analyses by logistic regression. A
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P-value < 0.05 was considered statistically significant.
Descriptive statistics are presented as medians and ranges
for continuous variables after checking for normality and
as proportions for categorical data.
Results
Baseline characteristics
Among patients presenting at Hai hospital (Hai district,
Kilimanjaro), TPC hospital (Lower Moshi, Kilimanjaro)
and Bondo Dispensary (Handeni, Tanga), 1100 partici-
pants were recruited (n = 240, n = 549 and n = 311, re-
spectively), of which 61.3 % (674) were female and 61.6 %
(678) were adults (≥15 years) (Table 2). The median age
was 24 years (range; 2 to 70 years), with males having a
lower median age than females (median, 15.5 and 26 years,
respectively). Generally, the malaria prevalence by mRDT
was 8.8 % (97/1100) while the remaining 91.2 % (1003/
1100) were malaria negative. The three sites varied sig-
nificantly in malaria prevalence; among children (2 to
14 years), the malaria prevalence were highest in par-
ticipating children attending TPC hospital with 25.4 %
(15/59) followed by 14.1 % (44/311) in Bondo dispens-
ary and 0 % in Hai hospital. Among adults (≥15 years),
the malaria prevalence were likewise highest in TPC
hospital at 13.9 % (35/252) followed by Bondo dispens-
ary at 1.3 % (3/238) and none in Hai hospital.
After excluding all malaria positive cases the preva-
lence of fever in children were highest in Hai hospital at
78.8 % (41/52), followed by TPC hospital at 52.3 %
(23/44) and Bondo dispensary at 22.8 % (61/267). Among
adults, the prevalence of fever were 53.0 % (115/217) at
TPC hospital, followed by Bondo dispensary at 40.4 %
(95/235) and lastly, in Hai hospital at 24.5 % (46/188).
Sero-prevalence of dengue and chikungunya among
febrile and afebrile participants
Among all febrile participants, the total prevalence of
dengue IgM positives was 1.3 % (5/381) all of which
were from participants residing nearby TPC hospital
(3.6 % (5/138) (Table 3). The prevalence of Dengue IgG
positives among febrile participants were as well low,
only 1.3 % (2/156) in Bondo dispensary, 1.1 % (1/87) in
Hai hospital and 1.4 % (2/138) in TPC hospital. Among
afebrile participants, the total prevalence of dengue IgM
positives was only 0.8 % (5/622) out of which 0.6 %
(2/346), 0.7 % (1/153) and 1.6 % (2/123) positives
were observed in samples from Bondo dispensary, Hai
hospital and TPC hospital, respectively. Conversely,
dengue IgG positives were also low at the three sites.
Generally, we observed high IgM sero-prevalence among
all participants while no difference between children 14.0 %
(51/363) and adults 13.1 % (84/640), (χ2 = 0.17; p = 0.6)
and IgG sero-prevalence was low with difference be-
tween children 3.0 % (11/363) and adults 5.9 (38/640),
(χ2 = 4.21; p = 0.04). The total number of chikungunya
IgM positives among febrile participants were 12.9 %
(49/381), and there were no difference observed between
children 12.0 % (14/49) and adults 13.3 % (34/49) (χ2 =
0.12; p = 0.7). No apparent differences between the sites
Table 2 Baseline characteristics of the studied population
(N = 1100)
Variable %(n)
Sites Bondo Hai TPC Total
n = 549 n = 240 n = 311 N = 1100
Sex Male 37.3 (205) 32.9 (79) 45.7 (142) 38.7 (426)
Female 62.7 (344) 67.1 (161) 54.3 (169) 61.3 (674)
Age Adults 56.6 (311) 21.7 (52) 19.0 (59) 38.4 (422)
Children 43.4 (238) 78.3 (188) 81.0 (252) 61.6 (678)
Total Malaria (mRDT)
Positive 8.6 (47) 0 (0) 16.1 (50) 8.8 (97)
Negative 91.4 (502) 0 (240) 83.9 (261) 91.2 (1003)
Malaria RDT n = 311 n = 52 n = 59 n = 422
*In children - Positive 14.1 (44) 0 (0) 25.4 (15) 14.0 (59)
Negative 85.9 (267) 100 (52) 74.6 (44) 86.0 (363)
Malaria RDT n = 238 n = 188 n = 252 n = 678
**In adults - Positive 1.3 (3) 0 (0) 13.9 (35) 5.6 (38)
Negative 98.7 (235) 100 (188) 86.1 (217) 94.4 (640)
aFever in children n = 267 n = 52 n = 44 n = 363
Positive 22.8 (61) 78.8 (41) 52.3 (23) 34.4 (125)
Negative 77.2 (206) 21.2 (11) 47.7 (21) 65.6 (238)
aFever in adults n = 235 n = 188 n = 217 n = 640
Positive 40.4 (95) 24.5 (46) 53.0 (115) 40.0 (256)
Negative 59.6 (140) 75.5 (142) 47.0 (102) 60.0 (384)
*p = 0.01
**p < 0.01
aAll malaria positive cases were excluded
Table 1 Primers and Probe sequences used in detection of dengue and chikungunya
Sequence name Primer sequence (5′–3′) Region, position Digital object identifier (DOI)
DENV-R GHRGAGACAGCAGGATCTCTG 3′UTR, 10674–10694 10.1016/S1995–7645(12)60055–8
DENV-F GACTAGYGGTTAGAGGAGACC 3′UTR, 10520–10541
DENV-P Cy5-AAGGACTAGMGGTTAGWGGAGACCC-BHQ2 3′UTR, 10610–10634
CHIKV-F CGTGGTGTACAAAGGTGACG E1, 10524
CHIKV-R ACG CCG GGTAGTTGACTATG E1, 11170 10.1002/jmv.23406
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were observed; 14.7 % (23/156) in Bondo dispensary,
13.8 % (12/87) in Hai hospital and 10.1 % (14/138) in TPC
hospital (χ2 = 1.46; p = 0.4), (Table 3). The total number of
IgG positives among febrile participants was lower; at
3.7 % (14/381) divided into 1.9 % (3/156) in Bondo
dispensary, 6.9 % (6/87) in Hai hospital and 3.6 % (5/138)
in TPC hospital (Table 3). Total number of IgG positives
among febrile participants was not different between
children 4.8 % (6/14) and adults 3.1 % (8/14) (χ2 = 0.66;
p = 0.4).
Among afebrile participants, the total number of
chikungunya IgM positives was higher, as compared
to the febrile participants, at 13.8 % (86/622), though
this was not significantly different (χ2 = 0.189; p = 0.6).
Furthermore, the number of IgM positives was signifi-
cantly different between the sites; 12.1 % (42/346) in
Bondo dispensary, 20.3 % (31/153) in Hai hospital and
10.6 % (13/123) in TPC hospital (χ2 = 7.24; p = 0.02). Like-
wise; the observed total chikungunya IgG positives was
lower than the IgM positives, at 5.6 % (35/622) though
with a significant difference between the sites; 3.2 %
(11/346) in Bondo dispensary, 6.5 % (10/153) in Hai
hospital and 11.4 % (14/123) in TPC hospital (χ2 = 11.81;
p = 0.03), (Table 3).
Probable dengue and chikungunya
Among all febrile participants, 8.7 % (33/381) and
74.2 % (283/381) cases met the WHO criteria for prob-
able dengue and chikungunya respectively. None of the
cases were positive for dengue while 4.2 % (11/263)
were confirmed acute chikungunya cases by PCR. Ten
of the acute chikungunya cases were from Bondo and a
single case came from Hai. Two of these cases were
children (2 to 14 years).
Association of chikungunya seropositivity and symptoms
In uni-variate analysis results, headache and joint pain
were significant predictors of chikungunya IgM seroposi-
tivity with OR = 3.03 (2.06–4.4), p < 0.01 and OR = 1.80
(1.25–2.59), p < 0.01 respectively. However when we com-
bined headache and joint pain we did not observe any
association, OR = 0.84 (0.55–1.26); p = 0.4. Joint pain were
marginally associated with chikungunya IgG seropositivity
OR = 0.51 (0.26–0.9), p = 0.05, Tables 4 and 5. Results of
laboratory test among participants are presented in
Additional file 1: Table 6.
Discussion
Diagnosis of infectious diseases in resource poor settings
is a challenge. In malaria endemic areas most febrile
illnesses have been and are treated as malaria cases due
to lack of diagnostic capacity to properly rule-out mal-
aria as a cause of fever and as well, identify alternative
fever-causing pathogens [14]. As for malaria, diagnosis
of dengue and chikungunya based on clinical presenta-
tion is difficult. Furthermore, similar presentations of
signs and symptoms in the initial stage of illness of
dengue and chikungunya have been a challenge to dis-
tinguish the two diseases clinically [38, 39]. Although,
the vast majority of clinical dengue and chikungunya
cases are self-limiting, however, in particularly diagnosis
of patients with dengue is important for patient manage-
ment in case of severe symptoms if done in a timely
manner.
This study was conducted in three sites in northern
Tanzania, each community have different characteristics
in terms of varying altitude and thus, malaria transmis-
sion that may had identified acute cases of dengue and
chikungunya infections and variations in prevalence of
serological markers of dengue and chikungunya between
the sites. Accordingly, the three sites differed in malaria
prevalence with TPC hospital having higher malaria
prevalence as compared to Bondo dispensary and Hai
hospital as based on mRDT diagnosis.
We observed few dengue IgM positive cases among
febrile participants in TPC hospital in Moshi (3.6 %) and
there were no confirmed acute dengue cases by PCR at
any sites. Evidence shows that viral RNA can be detected
in patients from 0–7 days following the onset of symp-
toms, which corresponds roughly to the duration of
fever while IgM is detected in 3 to 5 or more days after
the onset of illness/symptoms in the majority of infected
individuals [40]. Therefore, there is a possibility that
dengue IgM positive but PCR negative samples were
Table 3 Seroprevalence of dengue and chikungunya among febrile and afebrile participants in north-eastern Tanzania (N = 1003)
Febrile n (%) Afebrile n (%)
Sites Bondo Hai TPC Total Bondo Hai TPC Total
n = 156 n = 87 n = 138 n = 381 n = 346 n = 153 n = 123 n = 622
Dengue IgM a0 (0) 0 (0) 3.6 (5) 1.3 (5) a0.6 (2) 0.7 (1) 1.6 (2) 0.8 (5)
Dengue IgG a1.3 (2) 1.1 (1) 1.4 (2) 1.3 (5) a1.2 (4) 0.7 (1) 0 (0) 0.8 (5)
Chikungunya IgM 14.7 (23) 13.8 (12) 10.1 (14) 12.9 (49) 12.1 (42) 20.3 (31) 10.6 (13) 13.8 (86)
Chikungunya IgG a1.9 (3) 6.9 (6) 3.6 (5) 3.7 (14) 3.2 (11) 6.5 (10) 11.4 (14) 5.6 (35)
IgM Immunoglobulin M, IgG Immunoglobulin G
aDifference was calculated by Fishers exact test
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collected towards the end of the acute phase beyond the
viral RNA detection phase. Furthermore, the lack of
PCR confirmed cases in the study sites are suggestive of
the IgM positive cases having been imported rather than
locally transmitted. During the study, four cases who live
in Moshi were reported from the KCMC hospital in
Moshi, a few kilometres from the TPC study site, after
having visited Dar es Salaam during a large-scale dengue
outbreak in April-May, 2014. These cases were PCR-
confirmed by our study team (unpublished data). The
sampling period for the TPC site coincides somewhat
with the dengue outbreak in Dar es Salaam.
Table 4 Association of symptoms and chikungunya IgM seropositivity





OR (95 % CI) p-value OR (95 % CI) p-value
Fever
Yes 381 36.3 (49) 38.2 (332) 0.92 (0.63–1.34) 0.6 - -
No 622 63.7 (86) 61.8 (536) Reference
Rash
Yes 9 0 (0) 1.0 (9) - - - -
No 994 100 (135) 99.0 (859) Reference
Nausea
Yes 83 7.4 (10) 8.4 (73) 0.87 (0.43–1.73) 0.6 - -
No 920 92.6 (125) 91.6 (795) Reference
Headache
Yes 451 68.1 (92) 41.1 (359) 3.03 (2.06–4.46) <0.001 2.90 (1.88–4.48) <0.001
No 522 31.9 (43) 58.6 (509) Reference Reference
Joint pain
Yes 381 50.4 (68) 36.1 (313) 1.80 (1.25–2.59) 0.002 1.09 (0.72–1.65) 0.6
No 622 49.6 (67) 63.9 (555) Reference Reference
OR Odds ratio, CI Confident interval
Table 5 Association of symptoms and chikungunyaIg Gseropositivity





OR (95 % CI) p-value OR (95 % CI) p-value
Fever
Yes 381 28.6 (14) 38.5 (367) 0.64 (0.34–1.20) 0.1 0.76 (0.39–1.47) 0.4
No 622 71.4 (35) 61.5 (587) Reference Reference
Rash
Yes 9 0 (0) 0.9 (9) - - - -
No 994 100 (49) 99.1 (945) Reference
Nausea
Yes 83 6.1 (3) 8.4 (80) 0.71 (0.21–2.34) 0.5 - -
No 920 93.9 (46) 91.6 (874) Reference
Headache
Yes 451 40.8 (20) 45.2 (431) 0.83 (0.46–1.50) 0.5 - -
No 522 59.2 (29) 54.8 (523) Reference
Joint pain
Yes 381 24.5 (12) 38.7 (369) 0.51 (0.26–0.9) 0.05 0.56 (0.28–1.11) 0.1
No 622 75.5 (37) 61.3 (585) Reference Reference
OR Odds ratio, CI Confidence interval
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Only 1.3 % of the participants were IgG positive to
dengue infection. This is lower than the previously
reported (10.7 %) in Moshi by Hertz et al. [26]. This can
be explained by the fact that the study by Hertz et al. was
based at a referral hospital receiving cases from the whole
north-eastern Tanzania catchment area, while our study
was conducted in health facilities serving local communi-
ties in each site. Although cross-reactivity with other
flavivirus cannot be completely ruled-out, the sensitivity
and specificity of the IgG ELISA kits used in this study are
reported to be 99.2 % and 96.2 %, respectively when
compared to the hemagglutination-inhibition method and
thus it is unlikely that the observed results are due to
cross reactivity with other flavi-viruses.
Conversely, we identified a high sero-prevalence of
chikungunya IgM (12.9 %) among febrile participants
out of which 12.0 % were among febrile children. This is
the first report on chikungunya IgM positivity in the
study sites. The proportion of chikungunya IgM sero-
positivity was comparable between children and adults
thus indicating similar exposure among the two age
groups. The 12 % seropositivity observed in children
ismore than twice as high as previously reported by
Chipwaza et al. [41] in Kilosa, Morogoro (4.7 %). This
study found 5.6 % of afebrile participants presenting
with prior exposure to chikungunya infection as mea-
sured by IgG positivity. Since there is no routine diagno-
sis for this virus at the health facilities in the sites, it is
likely that such infections go unnoticed or when causing
fever end up being treated as other common infections
such as malaria or bacterial infections. Unexpectedly, we
observed that the number of chikungunya IgG positives
were lower than the number of IgM positives. While the
IgM positivity did not differ among children and adults,
IgG positivity was significantly higher in adults (5.9 %)
than in children (3.0 %). This is indicative of active cir-
culation of chikungunya in the study sites as supported
by PCR results, with adults having prior exposure which
also points to a possible endemicity and cumulative
increases in IgG seropositivity with age [42].
We identified an overall prevalence of 4.2 % of acute
chikungunya infections among study participants; with
Bondo dispensary having the highest number of cases
(n = 10, 2.0 %). This is somewhat lower than the previ-
ous reported in Kilimanjaro region of 7.9 % [22, 26]
however, taken together it seems that chikungunya,
most likely as opposed to dengue, was endemic and
actively circulating in North-eastern Tanzania at the
time of the study.
However, it is not known whether the chikungunya virus
was silent or been actively present in Tanzania because no
research has been done for the past 60 years since its
discovery [43] to document its distribution. Symptoms of
chikungunya infection last for approximately 5 days, during
which is the time the virus is present in the blood circula-
tion and can be detected by PCR. After the viremic phase,
sensitivity of diagnosis of acute infection is minimal [44] as
the level of virus declines. We have observed few PCR
positive in Hai and none in TPC (Lower Moshi) and this
could be due to timing of blood sampling in acute infection.
The present study showed a significant association
between clinical symptoms (joint pain and headache)
and the probability of positive diagnosis of chikungunya
IgM. These results are in line with other studies, that
reported headache, nausea, vomiting, myalgia, and rash
were associated with chikungunya infection [45, 46]. We
also observed association of chikungunya IgG seroposi-
tivity and joint pain. It is known that joint pain is one of
the clinical features for chikungunya infection and its
effect can persist for long [47–50]. However, these symp-
toms are common and non-specific, and thus could be
mistakenly identified as caused by a variety of other
febrile illnesses such as malaria, typhoid, dysentery, and
bacterial meningitis [51, 52] and pose a challenge to
differential diagnosis.
We did observe quite a low number of mRDT posi-
tives in the 3 sites; preliminary data suggest that, as
expected, a fraction of the mRDT negatives are plasmo-
dium positive when using a sensitive PCR method (data
not shown), and therefore the low parasitaemi as are
having no impact on fever/symptoms observed in partic-
ipants, nevertheless after excluding all malaria positive,
we found that 38.0 % of the remaining participants re-
ported fever. It is known that in many malaria endemic
areas where clear diagnosis cannot be established, all
fevers may still be treated as malaria [53]. Therefore, we
recommend establishment of better diagnosis of fever to
avoid over-treatment of other diseases.
Conclusions
This is the first seroprevalence report of dengue and
chikungunya among participants presenting with malaria-
like symptoms in three communities with distinct ecol-
ogies of in north-eastern Tanzania. Chikungunya virus
appears to be actively circulating in the population,
while dengue circulates in low level. Among malaria-
like symptoms, headache was associated with chikungunya
IgM seropositivity.
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